TITLE:
Efficacy of 1/3-Dose Verteporfin Photodynamic Therapy for Subacute Central Serous Chorioretinopathy
AUTHORS:
Li Xu, Qiushi Liu, Xiaotong Zhuang, Dongning Liu
KEYWORDS:
Subacute Central Serous Chorioretinopathy (CSC), 1/3-Dose Verteporfin Photodynamic Therapy (PDT), Subfoveal Choroidal Thickness (SCT), Neuroretinal Thickness (NRT), Central Foveal Thickness (CFT)
JOURNAL NAME:
Open Journal of Ophthalmology,
Vol.7 No.4,
November
17,
2017
ABSTRACT:
Purpose: To study the safety and efficacy of 1/3-dose verteporfin photodynamic therapy (PDT) for subacute central serous chorioretinopathy (CSC). Methods: In this case series, 59 eyes (59 patients) diagnosed with subacute CSC in Shenyang the 4th hospital from January 2014 to December 2015 were treated with 1/3-dose verteporfin PDT and followed up for at least 1 year. The symptoms and the diagnosed history were more than 3 months but shorter than 6 months. The central foveal thickness (CFT), neuroretinal thickness (NRT), height of subfoveal retinal fluid (SRF), and subfoveal choroidal thickness (SCT) were observed at baseline and after treated at 1, 2, 3, 6 and 12 months with EDI-OCT, Best-corrected visual acuity ( BCVA) was also studied at the same time. Results: After 1, 2, 3 and 6 months of 1/3-dose verteporfin PDT treatment, the BCVA improved significantly (P 0.05). The height of SRF changed significantly. There was no retinal pigment epithelium atrophy and choroidal neovascularization (CNV) in all cases after more than 12 months follow-up. Conclusion: Treatment of 1/3 dose verteporfin PDT could safely and effectively reduce expansion of choroidal vessel and choroidal choriocapillary, promoting absorbance of subretinal fluid for subacute CSC. 1/3-dose verteporfin PDT may be an alternative method to treat the subacute CSC.